Health Care • Biotechnology: Laboratory Analytical Instruments
$462.72 ▼ -17.35
(-3.61%)
MKT CAP: $45.46B • VOL: 1.34M
52W L $283 52W H $482
WAT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.17B | $2.96B | $2.96B |
| YoY Revenue Growth % | +7.0% | +0.1% | — |
| Gross Profit | $1.88B | $1.76B | — |
| Gross Margin % | 59.3% | 59.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $802.6M | $826.4M | $817.7M |
| Operating Margin % | 25.4% | 27.9% | 27.7% |
| Net Income (GAAP) | $642.6M | $637.8M | $642.2M |
| EBITDA (Normalized) | $916.5M | $932.9M | $924.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $652.6M | $762.1M | $602.8M |
| Capital Expenditures (CapEx) | $142.4M | $133.1M | $133.0M |
| Free Cash Flow (FCF) | $510.1M | $629.0M | $469.8M |
| FCF Margin % | 16.1% | 21.3% | 15.9% |
| Return on Invested Capital (ROIC %) | 21.7% | 20.9% | 4.1% |
| Cash & Short-Term Equivalents | $588.0M | $325.4M | — |
| Total Debt (Short + Long Term) | $947.0M | $1.63B | $6.07B |
| Total Stockholders' Equity | $2.56B | $1.83B | $12.45B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR WAT.